Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1–34) from rat lungs

Codrons, Valérie; Vanderbist, Francis; Ucakar, Bernard; Préat, Véronique; Vanbever, Rita

doi:10.1002/jps.20053

Cited by 78 publications

(29 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The insufflator has been used to deliver different powders from nanoparticles [89] to large porous particles [90,91]. The physicochemical characteristics of the powder, including particle size distribution, as measured by a variety of techniques have been reported to be essentially unaffected by passage through the device [67,90,92,89,93,94]. However, the position of the device in the trachea of the animal during powder delivery may affect the percentage of powder deposited in the different lung lobes [95].…”

Section: Direct Administration Methodsmentioning

confidence: 99%

In vivo animal models for drug delivery across the lung mucosal barrier☆

Cryan

Sivadas

García-Contreras

2007

Advanced Drug Delivery Reviews

130

View full text Add to dashboard Cite

Section: Direct Administration Methodsmentioning

confidence: 99%

In vivo animal models for drug delivery across the lung mucosal barrier☆

Cryan

Sivadas

García-Contreras

2007

Advanced Drug Delivery Reviews

130

View full text Add to dashboard Cite

“…In terms of safety, endogenous surfactants such as DPPC and albumin are some appropriate choices for pulmonary protein formulation. DPPC has been shown to enhance the permeation (absorption) of parathyroid hormone (1Y34) in rat lungs (139). Furthermore, spray-dried powders containing human growth hormone, lactose and DPPC in ratio of 20:20:60 by weight display earlier t max and higher absolute bioavailability than those of simple solution when administered via the pulmonary route (140).…”

Section: Absorption Enhancementmentioning

confidence: 99%

Particle Engineering for Pulmonary Drug Delivery

et al. 2007

View full text Add to dashboard Cite

With the rapidly growing popularity and sophistication of inhalation therapy, there is an increasing demand for tailor-made inhalable drug particles capable of affording the most efficient delivery to the lungs and the most optimal therapeutic outcomes. To cope with this formulation demand, a wide variety of novel particle technologies have emerged over the past decade. The present review is intended to provide a critical account of the current goals and technologies of particle engineering for the development of pulmonary drug delivery systems. These technologies cover traditional micronization and powder blending, controlled solvent crystallization, spray drying, spray freeze drying, particle formation from liquid dispersion systems, supercritical fluid processing and particle coating. The merits and limitations of these technologies are discussed with reference to their applications to specific drug and/or excipient materials. The regulatory requirements applicable to particulate inhalation products are also reviewed briefly.

show abstract

“…Typically liposomal protein formulations for inhalation are DPIs to ensure storage stability. They can be prepared by spray-drying optimized to achieve the optimal particle size for inhalation and to preserve the protein activity (Bosquillon et al, 2004;Codrons et al, 2004). Liposomal dry powder aerosols for β-glucuronidase based on dimyristoylphosphatyl choline:cholesterol (7:3) were successfully prepared by lyophilization and jet-milling (Lu and Hickey, 2005).…”

Section: Liposomes For Pulmonary Delivery Of Peptides and Proteinsmentioning

confidence: 99%